Literature DB >> 11796596

Anthrax spores make an essential contribution to vaccine efficacy.

Fabien Brossier1, Martine Levy, Michèle Mock.   

Abstract

Anthrax is caused by Bacillus anthracis, a gram-positive spore-forming bacterium. Septicemia and toxemia rapidly lead to death in infected mammal hosts. Currently used acellular vaccines against anthrax consist of protective antigen (PA), one of the anthrax toxin components. However, in experimental animals such vaccines are less protective than live attenuated strains. Here we demonstrate that the addition of formaldehyde-inactivated spores (FIS) of B. anthracis to PA elicits total protection against challenge with virulent B. anthracis strains in mice and guinea pigs. The toxin-neutralizing activities of sera from mice immunized with PA alone or PA plus FIS were similar, suggesting that the protection conferred by PA plus FIS was not only a consequence of the humoral response to PA. A PA-deficient challenge strain was constructed, and its virulence was due solely to its multiplication. Immunization with FIS alone was sufficient to protect mice partially, and guinea pigs totally, against infection with this strain. This suggests that spore antigens contribute to protection. Guinea pigs and mice had very different susceptibilities to infection with the nontoxigenic strain, highlighting the importance of verifying the pertinence of animal models for evaluating anthrax vaccines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11796596      PMCID: PMC127709          DOI: 10.1128/IAI.70.2.661-664.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

1.  Fulminant meningitis due to Bacillus anthracis in 11-year-old girl during Ramadan.

Authors:  M Berthier; J L Fauchere; J Perrin; B Grignon; D Oriot
Journal:  Lancet       Date:  1996-03-23       Impact factor: 79.321

2.  Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig.

Authors:  S F Little; G B Knudson
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

3.  Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity.

Authors:  P C Turnbull; M G Broster; J A Carman; R J Manchee; J Melling
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

4.  Role of toxin functional domains in anthrax pathogenesis.

Authors:  F Brossier; M Weber-Levy; M Mock; J C Sirard
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

5.  Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs.

Authors:  S F Little; B E Ivins; P F Fellows; A M Friedlander
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

6.  Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers.

Authors:  B W McBride; A Mogg; J L Telfer; M S Lever; J Miller; P C Turnbull; L Baillie
Journal:  Vaccine       Date:  1998-05       Impact factor: 3.641

7.  Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques.

Authors:  B E Ivins; M L Pitt; P F Fellows; J W Farchaus; G E Benner; D M Waag; S F Little; G W Anderson; P H Gibbs; A M Friedlander
Journal:  Vaccine       Date:  1998-07       Impact factor: 3.641

8.  Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity.

Authors:  P C Turnbull; S H Leppla; M G Broster; C P Quinn; J Melling
Journal:  Med Microbiol Immunol       Date:  1988       Impact factor: 3.402

9.  Construction of Bacillus anthracis mutant strains producing a single toxin component.

Authors:  C Pezard; E Duflot; M Mock
Journal:  J Gen Microbiol       Date:  1993-10

10.  Contribution of individual toxin components to virulence of Bacillus anthracis.

Authors:  C Pezard; P Berche; M Mock
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

View more
  52 in total

Review 1.  Development of an improved vaccine for anthrax.

Authors:  Stephen H Leppla; John B Robbins; Rachel Schneerson; Joseph Shiloach
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

Review 2.  Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors:  S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

3.  Identification of a protein subset of the anthrax spore immunome in humans immunized with the anthrax vaccine adsorbed preparation.

Authors:  Indira T Kudva; Robert W Griffin; Jeonifer M Garren; Stephen B Calderwood; Manohar John
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  Morphogenesis of the Bacillus anthracis spore.

Authors:  Rebecca Giorno; Joel Bozue; Christopher Cote; Theresa Wenzel; Krishna-Sulayman Moody; Michael Mallozzi; Matthew Ryan; Rong Wang; Ryszard Zielke; Janine R Maddock; Arthur Friedlander; Susan Welkos; Adam Driks
Journal:  J Bacteriol       Date:  2006-11-17       Impact factor: 3.490

5.  Fully virulent Bacillus anthracis does not require the immunodominant protein BclA for pathogenesis.

Authors:  J Bozue; C K Cote; K L Moody; S L Welkos
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

6.  Identification of a second collagen-like glycoprotein produced by Bacillus anthracis and demonstration of associated spore-specific sugars.

Authors:  Lashanda N Waller; Michael J Stump; Karen F Fox; William M Harley; Alvin Fox; George C Stewart; Mona Shahgholi
Journal:  J Bacteriol       Date:  2005-07       Impact factor: 3.490

7.  Search for Bacillus anthracis potential vaccine candidates by a functional genomic-serologic screen.

Authors:  Orit Gat; Haim Grosfeld; Naomi Ariel; Itzhak Inbar; Galia Zaide; Yehoshua Broder; Anat Zvi; Theodor Chitlaru; Zeev Altboum; Dana Stein; Sara Cohen; Avigdor Shafferman
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

8.  Localization and assembly of proteins comprising the outer structures of the Bacillus anthracis spore.

Authors:  Rebecca Giorno; Michael Mallozzi; Joel Bozue; Krishna-Sulayman Moody; Alex Slack; Dengli Qiu; Rong Wang; Arthur Friedlander; Susan Welkos; Adam Driks
Journal:  Microbiology (Reading)       Date:  2009-04       Impact factor: 2.777

9.  Microarray analysis of transposon insertion mutations in Bacillus anthracis: global identification of genes required for sporulation and germination.

Authors:  William A Day; Suzanne L Rasmussen; Beth M Carpenter; Scott N Peterson; Arthur M Friedlander
Journal:  J Bacteriol       Date:  2007-02-02       Impact factor: 3.490

10.  Saccharides cross-reactive with Bacillus anthracis spore glycoprotein as an anthrax vaccine component.

Authors:  Joanna Kubler-Kielb; Evgeny Vinogradov; Haijing Hu; Stephen H Leppla; John B Robbins; Rachel Schneerson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.